Screening for preeclampsia risk and prophylaxis with acetylsalicylic acid
- PMID: 37984937
- PMCID: PMC10662494
- DOI: 10.1503/cmaj.230620
Screening for preeclampsia risk and prophylaxis with acetylsalicylic acid
Conflict of interest statement
Competing interests: Venu Jain reports payment or honoraria from Ferring and Bayer. Dr. Jain is board director with the Society of Obstetricians and Gynaecologists of Canada (SOGC) and a member of the Guideline Management and Oversight Committee, SOGC. Emmanuel Bujold reports a grant to study the prediction of preeclampsia from the Canadian Institutes of Health Research and unrestricted support for research (providing free kits and laboratory reagents) from ThermoFisher BRAHMS. No other competing interests were declared.
References
-
- Duley L. The global impact of pre-eclampsia and eclampsia. Semin Perinatol 2009;33:130–7. - PubMed
-
- Goodlin RC, Haesslein HO, Fleming J. Aspirin for the treatment of recurrent toxaemia. Lancet 1978;2:51. - PubMed
-
- Beaufils M, Uzan S, Donsimoni R, et al. . Prevention of pre-eclampsia by early antiplatelet therapy. Lancet 1985;1:840–2. - PubMed
-
- Rolnik DL, Wright D, Poon LC, et al. . Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. N Engl J Med 2017;377:613–22. - PubMed
-
- Roberge S, Bujold E, Nicolaides KH. Aspirin for the prevention of preterm and term preeclampsia: systematic review and meta-analysis. Am J Obstet Gynecol 2018;218:287–93.e1. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources